How a move to ‘transform pharma R&D’ went south
Enlight Biosciences had an intriguing idea. Founded in 2008, when money in biotech was tight, the company would develop ways to make drug development smarter, more efficient, and cheaper. The plan, as one slide deck put it, was to “transform pharma R&D.”
A decade later, despite receiving interest from major drug companies, Enlight appears to have failed, STAT’s Kate Sheridan reports. The three companies it spun out are either shuttered, struggling to operate, or stalled in preclinical development.
“It was an experiment that was worth trying,” said Daphne Zohar, founder and CEO of PureTech, the Boston-based venture capital and biotech firm that started Enlight.
Read more.
A decade later, despite receiving interest from major drug companies, Enlight appears to have failed, STAT’s Kate Sheridan reports. The three companies it spun out are either shuttered, struggling to operate, or stalled in preclinical development.
“It was an experiment that was worth trying,” said Daphne Zohar, founder and CEO of PureTech, the Boston-based venture capital and biotech firm that started Enlight.
Read more.
No hay comentarios:
Publicar un comentario